Seqera Labs, a provider of data orchestration and workflow software for the life sciences, said Series A follows a period of strong growth, with revenue increasing 400% from a year on year and a tripling of employees in the past 12 months.
He explained how his flagship data analytics platform has also succeeded in expanding its footprint and achieving rapid adoption, being used by more than 150 leading pharmaceutical and biotech companies, including AstraZeneca, Janssen Pharmaceuticals and Oxford. Nanopore. Its technology has been used to discover and track the Alpha, Delta and Omicron variants of the COVID-19 virus.
The latest funding will help strengthen its team, as well as expand its product portfolio to cover the entire data analytics lifecycle.
Founded in 2018 as a spin-off from the Center for Genomic Regulation (CRG), following the initial success of Nextflow, Seqera seeks to accelerate discovery and therapeutic breakthroughs through fundamental open science software; it aims to empower scientists to assemble and deploy massively scalable data analysis pipelines in multi-cloud environments with minimal friction.
The plan for the future is to move beyond scientific workflows to encompass tool development, data management, reporting, infrastructure deployment, and interactive computing.
Jason Schneider of Addition said the biotech industry is changing and organizations need to quickly expand their capacity to process complex data at scale. “Seqera Labs products make this easier than ever and allow research teams to stay focused on their critical work.